Leishmania infantumleishmaniasis in corticosteroid – treated patients
| Autor: | Emanuele Nicastri, Maria Grazia Paglia, Piero Ghirga, Francesco Spinazzola, Silvia Pittalis, Michele De Marco, Pasquale Narciso |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Population Case Report Organ transplantation lcsh:Infectious and parasitic diseases Cutaneous leishmaniasis Adrenal Cortex Hormones medicine Animals Humans lcsh:RC109-216 Leishmania infantum education Immunodeficiency Aged education.field_of_study biology business.industry Leishmaniasis Immunosuppression Middle Aged Th1 Cells medicine.disease biology.organism_classification Infectious Diseases Visceral leishmaniasis Immunology Leishmaniasis Visceral Female business Immunosuppressive Agents |
| Zdroj: | BMC Infectious Diseases, Vol 6, Iss 1, p 177 (2006) BMC Infectious Diseases |
| ISSN: | 1471-2334 |
| DOI: | 10.1186/1471-2334-6-177 |
| Popis: | Background The number of leishmaniasis cases associated with immunosuppression has increased regularly over the past 20 years. Immunosuppression related to HIV infection, immunosuppressive treatment, organ transplantation, and neoplastic diseases increases the risk for Leishmania-infected people to develop visceral illness. Case presentation Three cases of Leishmania infantum leishmaniasis in corticosteroid (CS)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. Conclusion Physicians should recognise CS-treated patients as a population likely to be immunesuppressed. In immunodeficiency conditions, unusual forms of leishmaniasis can develop and foster the risk of a diagnostic delay and of poor response to therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink